Bioventus announced that Ken M. Reali has stepped down as Chief Executive Officer and as a member of the Board of Directors. The board has initiated a comprehensive search process to identify a permanent CEO.
Until a successor is named, the board has appointed Anthony Bihl as interim CEO, effective immediately. Bihl’s more than 35 years of industry experience includes former service as CEO and member of the Board of Managers of Bioventus from 2013 until his retirement in 2020.
“On behalf of the board and Bioventus employees, I want to thank Ken for his valuable contributions to Bioventus and his dedicated leadership over the past three years,” said William A. Hawkins, Bioventus’ executive chairman. “We are urgently looking to address our performance and execution, unlock long-term value and deliver on the expectations of our shareholders. As we search for a permanent successor, we believe Tony is uniquely positioned as the interim CEO to lead Bioventus through this transition given his previous experience, tenure and success at the company.”
Mr. Bihl said, “I look forward to working closely with the board and executive leadership team as interim CEO. Bioventus has a strong foundation, a differentiated portfolio of leading products that drive value for patients, and significant potential across large and growing addressable markets. I look forward to leveraging my prior executive leadership experience to stabilize the company, improve execution and enhance shareholder value as we deliver on the company’s mission.”
Bioventus announced that Ken M. Reali has stepped down as Chief Executive Officer and as a member of the Board of Directors. The board has initiated a comprehensive search process to identify a permanent CEO.
Until a successor is named, the board has appointed Anthony Bihl as interim CEO, effective immediately. Bihl’s more than 35 years of...
Bioventus announced that Ken M. Reali has stepped down as Chief Executive Officer and as a member of the Board of Directors. The board has initiated a comprehensive search process to identify a permanent CEO.
Until a successor is named, the board has appointed Anthony Bihl as interim CEO, effective immediately. Bihl’s more than 35 years of industry experience includes former service as CEO and member of the Board of Managers of Bioventus from 2013 until his retirement in 2020.
“On behalf of the board and Bioventus employees, I want to thank Ken for his valuable contributions to Bioventus and his dedicated leadership over the past three years,” said William A. Hawkins, Bioventus’ executive chairman. “We are urgently looking to address our performance and execution, unlock long-term value and deliver on the expectations of our shareholders. As we search for a permanent successor, we believe Tony is uniquely positioned as the interim CEO to lead Bioventus through this transition given his previous experience, tenure and success at the company.”
Mr. Bihl said, “I look forward to working closely with the board and executive leadership team as interim CEO. Bioventus has a strong foundation, a differentiated portfolio of leading products that drive value for patients, and significant potential across large and growing addressable markets. I look forward to leveraging my prior executive leadership experience to stabilize the company, improve execution and enhance shareholder value as we deliver on the company’s mission.”
Copy to clipboard 
